27617315|t|Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination
27617315|a|We investigated the extended use of Prostate Health Index (PHI) and percentage of [-2]pro-prostate-specific antigen (%p2PSA) in Chinese men with prostate-specific antigen (PSA) 10-20 ng/mL and normal digital rectal examination (DRE). All consecutive Chinese men with PSA 10-20 ng/mL and normal DRE who agreed for transrectal ultrasound (TRUS)-guided 10-core prostate biopsy were recruited. Blood samples were taken immediately before TRUS -guided prostate biopsy. The performances of total PSA (tPSA), % free-to-total PSA (% fPSA), %p2PSA, and PHI were compared using logistic regression, receiver operating characteristic, and decision curve analyses (DCA). From 2008 to 2015, 312 consecutive Chinese men were included. Among them, 53 out of 312 (17.0%) men were diagnosed to have prostate cancer on biopsy. The proportions of men with positive biopsies were 6.7% in PHI <35, 22.8% in PHI 35-55, and 54.5% in PHI >55 (chi-square test, p<0.001). The area under curves (AUC) of the base model including age, tPSA and status of initial/repeated biopsy was 0.64. Adding %p2PSA and PHI to the base model improved the AUC to 0.79 (p<0.001) and 0.78 (p<0.001), respectively, and provided net clinical benefit in DCA. The positive biopsy rates of Gleason 7 or above prostate cancers were 2.2% for PHI <35, 7.9% for PHI 35-55, and 36.4% for PHI >55 (chi-square test, p<0.001). By utilizing the PHI cutoff of 35 to men with PSA 10-20 ng/mL and normal DRE, 57.1% (178 of 312) biopsies could be avoided. Both PHI and %p2PSA performed well in predicting prostate cancer and high grade prostate cancer. The use of PHI and %p2PSA should be extended to Chinese men with PSA 10-20 ng/mL and normal DRE.
27617315	16	37	Prostate Health Index	T058	UMLS:C4084801
27617315	56	89	[-2]pro-prostate-specific antigen	T103	UMLS:C3710767
27617315	93	100	Chinese	T098	UMLS:C0152035
27617315	101	104	men	T098	UMLS:C0025266
27617315	110	135	prostate specific antigen	T103	UMLS:C0138741
27617315	159	185	digital rectal examination	T058	UMLS:C1384593
27617315	222	243	Prostate Health Index	T058	UMLS:C4084801
27617315	245	248	PHI	T058	UMLS:C4084801
27617315	268	301	[-2]pro-prostate-specific antigen	T103	UMLS:C3710767
27617315	303	309	%p2PSA	T103	UMLS:C3710767
27617315	314	321	Chinese	T098	UMLS:C0152035
27617315	322	325	men	T098	UMLS:C0025266
27617315	331	356	prostate-specific antigen	T103	UMLS:C0138741
27617315	358	361	PSA	T103	UMLS:C0138741
27617315	386	412	digital rectal examination	T058	UMLS:C1384593
27617315	414	417	DRE	T058	UMLS:C1384593
27617315	436	443	Chinese	T098	UMLS:C0152035
27617315	444	447	men	T098	UMLS:C0025266
27617315	453	456	PSA	T103	UMLS:C0138741
27617315	480	483	DRE	T058	UMLS:C1384593
27617315	499	521	transrectal ultrasound	T058	UMLS:C0373345
27617315	523	527	TRUS	T058	UMLS:C0373345
27617315	544	559	prostate biopsy	T058	UMLS:C0194804
27617315	576	589	Blood samples	T031	UMLS:C0178913
27617315	620	624	TRUS	T058	UMLS:C0373345
27617315	633	648	prostate biopsy	T058	UMLS:C0194804
27617315	670	679	total PSA	T058	UMLS:C2986589
27617315	681	685	tPSA	T058	UMLS:C2986589
27617315	718	724	%p2PSA	T103	UMLS:C3710767
27617315	730	733	PHI	T058	UMLS:C4084801
27617315	754	773	logistic regression	T062	UMLS:C0206031
27617315	814	837	decision curve analyses	T062	UMLS:C0936012
27617315	839	842	DCA	T062	UMLS:C0936012
27617315	880	887	Chinese	T098	UMLS:C0152035
27617315	888	891	men	T098	UMLS:C0025266
27617315	941	944	men	T098	UMLS:C0025266
27617315	950	959	diagnosed	T033	UMLS:C0011900
27617315	968	983	prostate cancer	T038	UMLS:C0376358
27617315	987	993	biopsy	T058	UMLS:C0005558
27617315	1014	1017	men	T098	UMLS:C0025266
27617315	1023	1040	positive biopsies	T033	UMLS:C1514241
27617315	1032	1040	biopsies	T058	UMLS:C0005558
27617315	1054	1057	PHI	T058	UMLS:C4084801
27617315	1072	1075	PHI	T058	UMLS:C4084801
27617315	1096	1099	PHI	T058	UMLS:C4084801
27617315	1105	1120	chi-square test	T170	UMLS:C0008041
27617315	1167	1177	base model	T170	UMLS:C3161035
27617315	1193	1197	tPSA	T058	UMLS:C2986589
27617315	1229	1235	biopsy	T058	UMLS:C0005558
27617315	1253	1259	%p2PSA	T103	UMLS:C3710767
27617315	1264	1267	PHI	T058	UMLS:C4084801
27617315	1275	1285	base model	T170	UMLS:C3161035
27617315	1286	1294	improved	T033	UMLS:C0184511
27617315	1392	1395	DCA	T062	UMLS:C0936012
27617315	1401	1416	positive biopsy	T033	UMLS:C1514241
27617315	1410	1416	biopsy	T058	UMLS:C0005558
27617315	1426	1444	Gleason 7 or above	T170	UMLS:C0332326
27617315	1445	1461	prostate cancers	T038	UMLS:C0376358
27617315	1476	1479	PHI	T058	UMLS:C4084801
27617315	1494	1497	PHI	T058	UMLS:C4084801
27617315	1519	1522	PHI	T058	UMLS:C4084801
27617315	1528	1543	chi-square test	T170	UMLS:C0008041
27617315	1572	1575	PHI	T058	UMLS:C4084801
27617315	1592	1595	men	T098	UMLS:C0025266
27617315	1601	1604	PSA	T103	UMLS:C0138741
27617315	1628	1631	DRE	T058	UMLS:C1384593
27617315	1652	1660	biopsies	T058	UMLS:C0005558
27617315	1684	1687	PHI	T058	UMLS:C4084801
27617315	1692	1698	%p2PSA	T103	UMLS:C3710767
27617315	1728	1743	prostate cancer	T038	UMLS:C0376358
27617315	1748	1774	high grade prostate cancer	T038	UMLS:C0376358
27617315	1787	1790	PHI	T058	UMLS:C4084801
27617315	1795	1801	%p2PSA	T103	UMLS:C3710767
27617315	1824	1831	Chinese	T098	UMLS:C0152035
27617315	1832	1835	men	T098	UMLS:C0025266
27617315	1868	1871	DRE	T058	UMLS:C1384593